Crim1 suppresses left ventricular hypertrophy

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Regenerative Medicine

Background:

• Left ventricular hypertrophy (LVH) is a major risk factor for heart failure and sudden cardiac death.
• Cysteine-rich transmembrane bone morphogenetic protein regulator 1 (Crim1) is crucial for heart development and highly expressed in cardiac tissue.
• The precise role of Crim1 in regulating ventricular hypertrophy remains to be elucidated.

Purpose of the Study:

• To investigate the hypothesis that Crim1 exerts an inhibitory effect on ventricular hypertrophy.
• To explore the relationship between angiotensin receptor type 1 (AT1R) inhibition and Crim1 expression.
• To evaluate Crim1's potential as a therapeutic target for cardiac hypertrophy.

Main Methods:

• Primary rat ventricular myocytes were subjected to mechanical stretch to induce hypertrophy, followed by treatment with telmisartan or Ad-Crim1.
• Rat ventricular hypertrophy was induced via abdominal aortic coarctation (AAC) and treated with telmisartan, Ad-Crim1, or an empty adenovirus vector.
• Crim1 expression levels were assessed in hypertrophic and control conditions.

Main Results:

• Crim1 expression was found to be downregulated in hypertrophic ventricles.
• Telmisartan treatment significantly upregulated Crim1 expression in the left ventricle, both in vitro and in vivo.
• Overexpression of Crim1 via Ad-Crim1 infection or telmisartan treatment effectively inhibited both in vitro and in vivo ventricular hypertrophy.

Conclusions:

• Crim1 demonstrates a significant suppressive function against ventricular hypertrophy.
• Modulating Crim1 expression presents a novel therapeutic strategy for treating cardiac hypertrophy.
• Targeting Crim1 may offer a new avenue for managing heart failure and sudden death associated with LVH.